The First Affiliated Hospital of Xi'an Jiaotong University, the National Engineering Research Center for Biomaterials at Sichuan University, and other partner institutions jointly announced the successful development of an ECMO system with long-acting, stable anti-freezing coating. This ECMO system, the result of 5 years of research and development, will enter the market along with other medical equipment featuring advanced biocompatibility developed independently in China.

ECMO, to some extent, represents the highest critical disease treatment capability of a hospital, a region, or even a nation. ECMO removes blood from the patient's body, oxygenates it, and removes carbon dioxide through an artificial lung before pumping the rejuvenated blood back into the patient.

The successful development of the ECMO system with long-acting stable anti-freezing coating marks progress in medical apparatuses in China. It is expected to break technical barriers, reduce the price of ECMO, significantly benefit patients, and save more lives.